New drug EO-3021 tested in advanced cancer patients
NCT ID NCT05980416
First seen Nov 14, 2025 · Last updated May 23, 2026 · Updated 24 times
Summary
This early-stage study tested an experimental drug called EO-3021 in adults with advanced solid tumors, especially stomach cancer, that have a specific marker (CLDN18.2). The main goals were to check safety and find the right dose. The study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Atrium Health/Wake Forest University
Charlotte, North Carolina, 28204, United States
-
City of Hope
Duarte, California, 91010, United States
-
Georgetown University
Washington D.C., District of Columbia, 20007, United States
-
Henry Ford Cancer
Detroit, Michigan, 48202, United States
-
Johns Hopkins University - Sibley Memorial Hospital
Washington D.C., District of Columbia, 20016, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mary Crowley Cancer Research
Dallas, Texas, 75230, United States
-
Mayo Clinic
Phoenix, Arizona, 85054, United States
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
National Cancer Center Hospital
Chuo Ku, Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East
Kashiwa-shi, Chiba, 277-8577, Japan
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
Samsung Medical Center
Seoul, South Korea
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Sarah Cannon Research Institute at Florida Cancer Specialists
Orlando, Florida, 32827, United States
-
UW Carbone Cancer Center - Cancer Connect
Madison, Wisconsin, 53792, United States
-
Yale - Smilow Cancer Hospital
New Haven, Connecticut, 06519, United States
-
Yonsei University
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.